Skip to content

Early diagnostic value of plasma ELABELA levels in diabetic cardiomyopathy

Early diagnostic value of plasma ELABELA levels in diabetic cardiomyopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102638
Enrollment
Unknown
Registered
2025-05-16
Start date
2024-07-05
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic cardiomyopathy

Interventions

Diastolic with myocardial disease:None
Diabetes alone group:None
Diastolic dysfunction alone group:None
Control group:None

Sponsors

Fuxing Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Confirmed diagnosis of diabetes mellitus: diagnosed as diabetic in conjunction with the 2024 ADA Standards for the Medical Management of Diabetes Mellitus; 2) Diagnosis of diastolic dysfunction: combined with the 2023 European Heart Association Heart Failure Guidelines, diastolic dysfunction was diagnosed according to echocardiography; 3) Diagnostic criteria for diabetic cardiomyopathy: there is no relevant diagnostic gold standard, combined with the definition of diabetic cardiomyopathy and related literature, mainly based on exclusionary diagnosis, i.e., diabetic patients with clear evidence of cardiac insufficiency, except for hypertension, coronary heart disease, cardiac insufficiency due to heart valve disease; 4) All of the above patients met the age >18 years old adults with complete medical records.

Exclusion criteria

Exclusion criteria: 1. Patients with evidence of previous myocardial infarction, valves, or congenital heart disease; 2. Other patients with mental system diseases and consciousness dysfunction; 3. Patients with severe hepatic and renal insufficiency; 4. Malignant tumors, autoimmune deficiencies; 5. Hematologic diseases; 6. Patients who refuse this study.

Design outcomes

Primary

MeasureTime frame
plasma ELABELA values; B-type Natriuretic Peptide (BNP);

Secondary

MeasureTime frame
interleukin 6 value;

Countries

China

Contacts

Public ContactDuan Wenkai

Fuxing Hospital of Capital Medical University

dwk0625@163.com+86 178 6069 1192

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026